Nebenwirkungen · Ibrance
IBRANCE 75 mg hard capsules IBRANCE 100 mg hard capsules IBRANCE 125 mg hard capsules · Abschnitt 4.8 · PDF-Seite 10
HOS-132473 · Präparat HOS-097230
Table 4. Adverse reactions based on pooled dataset from 3 randomised studies (N=872) and during post-marketing experience System organ class All Grades Grade 3 Grade 4 Frequency n (%) n (%) n (%) Preferred terma (PT) Infections and infestations Very common Infectionsb 516 (59.2) 49 (5.6) 8 (0.9) Blood and lymphatic system disorders Very common Neutropeniac 716 (82.1) 500 (57.3) 97 (11.1) Leukopeniad 424 (48.6) 254 (29.1) 7 (0.8) Anaemiae 258 (29.6) 45 (5.2) 2 (0.2) Thrombocytopeniaf 194 (22.2) 16 (1.8) 4 (0.5) Common Febrile neutropenia 12 (1.4) 10 (1.1) 2 (0.2) Metabolism and nutrition disorders Very common Decreased appetite 152 (17.4) 8 (0.9) 0 (0.0) Nervous system disorders Common Dysgeusia 79 (9.1) 0 (0.0) 0 (0.0) Eye disorders Common Vision blurred 48 (5.5) 1 (0.1) 0 (0.0) Lacrimation increased 59 (6.8) 0 (0.0) 0 (0.0) Dry eye 36 (4.1) 0 (0.0) 0 (0.0) Vascular disorders Common Venous thromboembolismj 28 (3.2) 11 (1.3) 7 (0.8) Respiratory, thoracic and mediastinal disorders Common Epistaxis 77 (8.8) 0 (0.0) 0 (0.0) ILD/pneumonitisi 12 (1.4) 1 (0.1) 0 (0.0)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage 1e54f3c158b25965dd599eb2057cefb9bcc81f8e80cebd9e6b2009a229dfdbda · Zeichen 1893–4001 im Abschnitt